The Nurse View.

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Perspectives on Triple-Negative Breast Cancer

T-Cell Exhaustion: Can We Overcome It in Cancer?

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction to Checkpoint Inhibitors

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Basics of Immunotherapy Potential Therapeutic Targets.

Best Practices in Metastatic Colorectal Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Evolving Concepts in the Management of Head and Neck Cancers

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Advances in Gastrointestinal Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

The Changing Field of Melanoma: Ipilimumab.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Challenges and Opportunities

Preparing for Checkpoint Inhibitors in Breast Cancer

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

The Nurse View

Introduction

Checkpoint Inhibition

Indications in GI Cancers MSI-High/dMMR Solid Tumors

Indications in GI Cancers MSI-H/dMMR Metastatic CRC

Indications in GI Cancers Advanced Gastric/GE Junction Cancers

Indications in GI Cancers Where Biomarkers Are Not Needed

Cases Where Checkpoint Inhibitors May Be Contraindicated -- or Require Close Consultation With the Oncologist

Microsatellite Instability

Genetic Testing

Biomarkers PD-L1

Biomarkers General Discussion

irAEs

irAEs Monitoring and Patient Education

Immunotherapy vs Chemotherapy AEs

Overview of Management Principles of irAEs

Considerations in the Management of irAEs

Case A 45-Year-Old Man With Colorectal Cancer

Patient Has Tumor That Is MSI-H

Educating the Patient

Patient Undergoes Treatment With a Checkpoint Inhibitor

Managing Immune-Related Hepatitis

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)